Anastrozole appears to be an effective and well tolerated endocrine option for the treatment of postmenopausal women with hormone-sensitive early breast cancer.
Based on results from an international trial of 9366 women from 21 countries, researchers believe that doctors now have a choice of anastrozole or tamoxifen therapy.
The women were divided into three groups: 3,125 were randomly assigned anastrozole, 3,116 tamoxifen, and 3,125 a combination of the two. Median follow-up was 33.3 months.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!